Pharma Update

Alzheimer's disease: Continuing to invest in high unmet need area Leveraging key learnings to develop next generation therapies Clinical development program in Alzheimer's disease Roche Neurology Update Roche IR Event Oct 2023 AD program strategy NME MOA Phl Ph II Ph III Selecting the right population 888 Having the right endpoints Bepranemab Anti-tau mAb Trontinemab Anti-Aẞ mAb Semorinemab Anti-tau mAb Ph Il completed Biomarker Ability to cross the enabled diagnosis blood brain barrier 0 GSM Small molecule Ph I completed • Using prior experience and key learnings to develop effective clinical trials Leading diagnostic solutions, including screening and confirmatory tests, developing novel blood- based and digital biomarker options • Innovative Brain Shuttle technology to enable superior penetration of BBB, leading to deeper and faster Aẞ reduction - potential for better efficacy Investigating MoAs to target various stages of the anti-amyloid cascade with GSM acting early in the pathological process and anti-tau mAbs acting at the end of the cascade . Ph I dose escalation for trontinemab and FIH data for GSM to be presented at CTAD 2023 on Oct 24-27th AD=Alzheimer's disease; BBB-blood brain barrier; mAb-monoclonal antibody; Aẞ-Amyloid ẞ; GSM-gamma secretase modulator; FIH=first in human; MoA-Mode of action 108

View entire presentation